FDA public meeting on device third-party review planned for mid-June.
This article was originally published in The Gray Sheet
Executive SummaryFDA PUBLIC MEETING ON THIRD-PARTY DEVICE REVIEW is tentatively scheduled for mid-June, according to agency staffers. The meeting is designed to give interested parties an opportunity to provide input to FDA on the mechanics and scope of a pilot third-party review program planned by the agency. FDA intends to announce the details of the meeting in the next few weeks, possibly through a Federal Register notice.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.